Leivonen M K, Saario I A, Peltokallio P, Tuominen L, Kalima T V
Br J Cancer. 1986 Nov;54(5):837-40. doi: 10.1038/bjc.1986.248.
The data for this study, consisting of 300 females treated for breast cancer in 1951-1961, were evaluated in order to ascertain when excess mortality from breast cancer disappears and what would be an appropriate follow-up period for investigational purposes. The clinical stages of the patients were classified as follows: 23.3%, stage I; 49%, stage II; 20.3%, stage III and 7.3%, stage IV. Halsted's radical mastectomy was performed in 79.7% of the cases. Every patient was given radiotherapy. Two hundred and ninety-eight patients could be followed until death or up to the present. Forty-five patients (16%) were still alive. The survival rate over a 20-year period for the various stages was as follows: stage I, 46.1%; stage II, 22.7% and stage III, 10.9%. Only 26% of the patients with stage I died of breast cancer, while the respective figures for stage II were 57% and stage III, 70%. The death rate from the cancer diminished with time in every stage especially 10 years after primary treatment. After this the observed survival rate curves were almost parallel with the expected curves. Our data show that for follow-up studies a 5-year follow-up is good and a 10-year follow-up is very good to show the trend in the treatment of breast cancer.
本研究的数据来自于1951年至1961年间接受乳腺癌治疗的300名女性，对这些数据进行评估以确定乳腺癌的超额死亡率何时消失，以及用于研究目的的合适随访期是多久。患者的临床分期如下：I期占23.3%；II期占49%；III期占20.3%；IV期占7.3%。79.7%的病例实施了Halsted根治性乳房切除术。每位患者均接受了放射治疗。298名患者能够随访至死亡或直至目前。45名患者（16%）仍然存活。各分期20年的生存率如下：I期为46.1%；II期为22.7%；III期为10.9%。I期患者中仅26%死于乳腺癌，而II期和III期的相应数字分别为57%和70%。各分期的癌症死亡率随时间下降，尤其是在初次治疗后10年。在此之后，观察到的生存率曲线几乎与预期曲线平行。我们的数据表明，对于随访研究，5年随访效果良好，10年随访对于显示乳腺癌治疗趋势非常好。
